A local drug delivery system based on visible light-cured glycol chitosan and doxorubicin⋅hydrochloride for thyroid cancer treatment <i>in vitro</i> and <i>in vivo</i>

Yoo, Young-Tae; Yoon, Sun Jung; Kim, So Yeon; Lee, Deok-Won; Um, Sewook; Hyun, Hoon; Hong, Sung Ok; Yang, Dae Hyeok

doi:10.1080/10717544.2018.1507058

Cited by 28 publications

(43 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among hydrogel systems, an injectable hydrogel is valuable, both because it can directly deliver anticancer drugs near cancer tissues by local injection and because it has a potential for drug loading in the matrices. In our previous studies, the visible light-cured GC hydrogel system was found to be a potent local drug-delivery carrier because of its injectability and the fact that it allows anticancer drugs to be controllably released in a sustained manner [10][11][12].…”

Section: Discussionmentioning

confidence: 99%

“…We have previously reported that the GC hydrogel has porous structure together with interconnectivity [10][11][12]. These structural properties resulted in in vivo anticancer effects against solid cancers when the GC hydrogel was used as the local anticancer drug-delivery system [10][11][12]. Therefore, it is assumed that GDHCP has a superior anticancer effect against osteosarcoma in vitro and in vivo (Figures 3-8).…”

Section: Discussionmentioning

confidence: 99%

“…The methacrylic group was conjugated to GC for photo-curing [10][11][12]. GC (0.003 mmol, 1.5 g) was dissolved in water (500 mL).…”

Section: Preparation Of Doxorubicin·hydrochloride (Dox·hcl) And/or Hpmentioning

confidence: 99%

“…Although systemic drug-delivery systems are efficient, their therapeutic applications are sometimes limited by complicated preparation. Hydrogel-medicated local drug delivery systems are capable of directly delivering anticancer drugs to targeted sites without complicated procedures because they can be implanted near cancer tissues [10][11][12]. We have already reported that a visible light-cured injectable glycol chitosan (GC) hydrogel-based local drug-delivery system can be used as an anticancer drug carrier for treatment of several solid cancers [10][11][12].…”

Section: Introductionmentioning

confidence: 99%

“…Hydrogel-medicated local drug delivery systems are capable of directly delivering anticancer drugs to targeted sites without complicated procedures because they can be implanted near cancer tissues [10][11][12]. We have already reported that a visible light-cured injectable glycol chitosan (GC) hydrogel-based local drug-delivery system can be used as an anticancer drug carrier for treatment of several solid cancers [10][11][12]. Additionally, beta-cyclodextrin (β-CD) is used as a nanosized drug carrier for anticancer drugs because it has a cavity that is similar in size to the drugs [13,14].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Doxorubicin·Hydrochloride/Cisplatin-Loaded Hydrogel/Nanosized (2-Hydroxypropyl)-Beta-Cyclodextrin Local Drug-Delivery System for Osteosarcoma Treatment In Vivo

et al. 2019

Self Cite

View full text Add to dashboard Cite

Osteosarcoma (OSA) is a difficult cancer to treat due to its tendency for relapse and metastasis; advanced methods are therefore required for OSA treatment. In this study, we prepared a local drug-delivery system for OSA treatment based on doxorubicin·hydrochloride (DOX·HCl)/cisplatin (CP)-loaded visible light-cured glycol chitosan (GC) hydrogel/(2-hydroxypropyl)-beta-cyclodextrin (GDHCP), and compared its therapeutic efficiency with that of DOX·HCl-and CP-loaded GC hydrogels (GD and GHCP). Because of diffusion driven by concentration gradients in the swollen matrix, the three hydrogels showed sustained releases of DOX·HCl and CP over 7 days, along with initial 3-h bursts. Results of in vitro cell viability and in vivo animal testing revealed that GDHCP had a stronger anticancer effect than GD and GHCP even though there were no significant differences. Body weight measurement and histological evaluations demonstrated that the drug-loaded GC hydrogels had biocompatibility without cardiotoxicity or nephrotoxicity. These results suggested that GDHCP could be a good platform as a local drug-delivery system for clinical use in OSA treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…The methacrylic group was conjugated to GC for photo-curing [10][11][12]. GC (0.003 mmol, 1.5 g) was dissolved in water (500 mL).…”

Section: Preparation Of Doxorubicin·hydrochloride (Dox·hcl) And/or Hpmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Doxorubicin·Hydrochloride/Cisplatin-Loaded Hydrogel/Nanosized (2-Hydroxypropyl)-Beta-Cyclodextrin Local Drug-Delivery System for Osteosarcoma Treatment In Vivo

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

Tumor‐Targeting Glycol Chitosan Nanoparticles for Cancer Heterogeneity

et al. 2020

View full text Add to dashboard Cite

liposomes (Doxil; liposomal doxorubicin (DOX), Onivyde; liposomal irinotecan, Vyxeos; liposomal daunorubicin plus cytarabine) and albumin nanoparticles (Abraxane; albumin nanoparticle-bound paclitaxel), being approved for clinical use and other nanocarriers being at different stages of clinical development. [2] Despite recent research and development of nanomedicines, the success rate of clinical translation remains poor, with patients in clinical settings benefitting from nanomedicines only through a reduction in side effects. [3] This is primarily because the enhanced accumulation of nanoparticles at tumor sites was initially overvalued in preclinical settings, with insufficient consideration given to tumor heterogeneity and complexity. [4] An analysis of studies published from 2005 to 2015 on the efficiency of nanoparticle delivery found that only 0.7% of the administered dose of nanoparticles was delivered to the tumor, irrespective of the materials, targeting strategy, hydrodynamic diameter, zeta potential, shape of nanoparticles, tumor model, and cancer type. [5] This low efficiency of delivery has prompted investigations to determine whether any key factors were omitted in the design and development of nanocarriers. A fundamental understanding of the key factors determining the tumor-targeting ability of nanoparticles is therefore required to optimize the design and development of nanoparticles with enhanced efficiency of delivery to tumors. Although many studies have assessed the impact of nanocarrier properties on the efficiency of targeted delivery, the effects of different factors are interconnected and often in opposition. For example, coating the surfaces of nanocarriers with poly(ethylene glycol) (PEG) extends their circulation in the blood by minimizing their detection by the immune system, thus contributing to targeted accumulation. However, PEG also reduces the uptake of nanocarriers by tumor tissue or tumor cells, reducing the accumulation of nanocarriers in tumors. Therefore, integrated analysis of the key factors found in a single type of nanoparticle with excellent tumor-targeting ability may provide insights into the entire procedure of developing new tumor-targeting nanocarriers. The relatively moderate therapeutic efficacy of nanomedicines in clinical settings may be due in part to tissue heterogeneity. The clinical benefits of nanomedicines have been reported to be highly variable and limited compared with their Nanomedicine is extensively employed for cancer treatment owing to its unique advantages over conventional drugs and imaging agents. This increased attention to nanomedicine, however, has not fully translated into clinical utilization and patient benefits due to issues associated with reticuloendothelial system clearance, tumor heterogeneity, and complexity of the tumor microenvironment. To address these challenges, efforts are being made to modify the design of nanomedicines, including optimization of their physiochemical properties, active targeting, and response to stimuli, but...

show abstract

Recent Advances in 3D Printing of Photocurable Polymers: Types, Mechanism, and Tissue Engineering Application

Randhawa

Dutta

Ganguly

et al. 2022

Macromolecular Bioscience

View full text Add to dashboard Cite

The conversion of liquid resin into solid structures upon exposure to light of a specific wavelength is known as photopolymerization. In recent years, photopolymerization‐based 3D printing has gained enormous attention for constructing complex tissue‐specific constructs. Due to the economic and environmental benefits of the biopolymers employed, photo‐curable 3D printing is considered an alternative method for replacing damaged tissues. However, the lack of suitable bio‐based photopolymers, their characterization, effective crosslinking strategies, and optimal printing conditions are hindering the extensive application of 3D printed materials in the global market. This review highlights the present status of various photopolymers, their synthesis, and their optimization parameters for biomedical applications. Moreover, a glimpse of various photopolymerization techniques currently employed for 3D printing is also discussed. Furthermore, various naturally derived nanomaterials reinforced polymerization and their influence on printability and shape fidelity are also reviewed. Finally, the ultimate use of those photopolymerized hydrogel scaffolds in tissue engineering is also discussed. Taken together, it is believed that photopolymerized 3D printing has a great future, whereas conventional 3D printing requires considerable sophistication, and this review can provide readers with a comprehensive approach to developing light‐mediated 3D printing for tissue‐engineering applications.

show abstract

A local drug delivery system based on visible light-cured glycol chitosan and doxorubicin⋅hydrochloride for thyroid cancer treatment in vitro and in vivo

Cited by 28 publications

References 19 publications

Doxorubicin·Hydrochloride/Cisplatin-Loaded Hydrogel/Nanosized (2-Hydroxypropyl)-Beta-Cyclodextrin Local Drug-Delivery System for Osteosarcoma Treatment In Vivo

Doxorubicin·Hydrochloride/Cisplatin-Loaded Hydrogel/Nanosized (2-Hydroxypropyl)-Beta-Cyclodextrin Local Drug-Delivery System for Osteosarcoma Treatment In Vivo

Tumor‐Targeting Glycol Chitosan Nanoparticles for Cancer Heterogeneity

Recent Advances in 3D Printing of Photocurable Polymers: Types, Mechanism, and Tissue Engineering Application

Contact Info

Product

Resources

About